Stock AnalizAbsci Corp ABSI
Biotechnology: Commercial Physical & Biological Resarch · IPO 2021 · data as of November 13, 2026
Absci Corp (ABSI) is a healthcare company listed in the US with a market value of about $1.5B. In the twelve months to September 30, 2026 it had revenue of $1M and net income of -$126M, a net margin of -8451.3%.
Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of -10% a year, a 5-year average ROIC of -39%.
Score: 0.6 / 5
Checks passed
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 6 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Revenue | $1M | $3M | $5M | $6M | $6M | $5M | $5M |
| Net income | -$126M | -$115M | -$103M | -$111M | -$105M | -$101M | -$14M |
| Free cash flow | -$113M | -$94M | -$73M | -$65M | -$98M | -$99M | -$13M |
| EPS (diluted) | $-0.78 | $-0.84 | $-0.94 | $-1.20 | $-1.15 | $-2.08 | $-3.19 |
| Net margin | -8451.3% | -4113.7% | -2274.1% | -1933.7% | -1825.4% | -2111.2% | -300.3% |
| ROIC | — | -48.8% | -45.5% | -47.7% | -36.1% | -18.2% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 11 analysts is $15.09, 79% above the current price; targets range from $10.00 to $20.00; the consensus rating is “Strong buy”; expected EPS is $-0.80 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Absci pay a dividend?
Not currently.
Is Absci a good stock to buy?
We do not give buy or sell advice. Absci scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.